07:00 , Jun 9, 2008 |  BioCentury  |  Strategy

Adding shots on goal

A long-standing critique of German biotech companies is that they are too small and rely too much on a single lead program. Two companies last week took steps to change that equation. 4SC AG for...
07:00 , Oct 16, 2006 |  BC Week In Review  |  Company News

Axaron, Lion bioscience deal

LIO completed its previously announced acquisition of Sygnis Bioscience GmbH & Co. KG, a new company that was formed to take over the assets of neurology company Axaron (see BioCentury, July 10). Axaron Bioscience AG...
07:00 , Aug 28, 2006 |  BioCentury  |  Finance

An angel's collection

An angel's collection An angel's collection SAP co-founder Dietmar Hopp's family has invested more than E200M in biotech companies since the bubble burst in 2000, and now plans to build clusters in cancer and CNS....
07:00 , Jul 10, 2006 |  BC Week In Review  |  Company News

Axaron, Lion bioscience deal

German investor Dietmar Hopp plans to form a new company specializing in CNS diseases by combining LIO and Axaron. The newco will combine LIO's listing and cash with Axaron's AX200 , a neuroprotectant that is...
07:00 , Jul 10, 2006 |  BioCentury  |  Finance

Hopp's repackaging project

Some nifty financial footwork is pushing two members of Germany's struggling biotech class of 1997 together to create a new CNS company. The assets of Axaron Bioscience AG have been transferred into a new corporate...
01:20 , Jul 7, 2006 |  BC Extra  |  Company News

Hopp to combine Lion, Axaron

German investor Dietmar Hopp plans to form a new company specializing in CNS diseases by combining Lion bioscience (FSE:LIO) and Axaron (Heidelberg, Germany). The newco will combine LIO's listing and cash with Axaron's AX200 ,...
08:00 , Jan 2, 2006 |  BC Week In Review  |  Company News

Axaron board of directors update

Axaron Bioscience AG , Heidelberg, Germany   Business: Functional genomics, Neurology   Appointed: Joachim Scholz, deputy head of the corporate legal department at BASF AG ; he replaces Michael Kramer, who departed  ...
08:00 , Dec 12, 2005 |  BioCentury  |  Strategy

Affitech deals

Affitech deals Since 2001, Affitech has closed four technology licensing deals as well as seven therapeutic collaborations in cancer, infectious and immune diseases. (A) Not active due to Axaron's change of focus Partner Date Focus...
07:00 , May 2, 2005 |  BC Week In Review  |  Company News

Axaron board of directors update

Axaron Bioscience AG , Heidelberg, Germany   Business: Functional genomics, Neurology   Appointed: Alfred Hackenberger, president of BASF AG’s Competence Center Specialty Chemicals Research  ...
08:00 , Jan 3, 2005 |  BioCentury  |  Tools & Techniques

Axaron's functional regeneration

In stroke, brain damage is enhanced by the formation of oxygen radicals that send neurons in a vast area around the primary site into apoptosis. Among the companies trying to develop neuroprotectants to limit this...